Evolving our science to solve complex healthcare challenges

Dave Powell on why LifeArc is evolving the way we do our science – and the difference we hope it will make to people’s lives.

2022 wrapped – our highlights from a pivotal year

We’ve seen some exciting scientific progress, forged new partnerships and launched some new landmark initiatives.

LifeArc partners with EMBARC to improve healthcare for people living with bronchiectasis

Three-year partnership to improve healthcare for thousands of people across Europe living with bronchiectasis.

MND Collaborative Partnership cautiously welcomes new Government funding

We cautiously welcome the Government's announcement on how their £50m commitment into MND research will be spent.

Repurposed flu medicine could help under 60s recover faster from COVID-19

Results of an international repurposing study show favipiravir could help with COVID-19.

LifeArc bolsters executive team with communications expertise

Welcome to Anna Tomlinson, who joins LifeArc as our first Chief Communications Officer.

LifeArc announces £10m funding call for new chronic respiratory infection therapies

First major funding call announced as part of our £100m Chronic Respiratory Infection Translational Challenge

£100m programme to transform care for people living with chronic lung conditions

More than 300,000 people in the UK are living with bronchiectasis and more than 10,000 have been diagnosed with cystic fibrosis.

LifeArc responds to the Government’s renewed pledge to increase R&D funding

LifeArc CEO Dr Melanie Lee welcomes the Government’s restatement of its commitment to increase R&D funding in today’s Autumn statement: “Today the Chancellor made it clear that UK life science is a key driver of growth. “I am delighted that promises to raise the research and development (R&D) budget have been protected. It is the […]